Joseph L Backer

US Patent:

55631304, Oct 8, 1996

Filed:

Dec 13, 1994

Appl. No.:

8/355371

Inventors:

Joseph M. Backer - Tenafly NJ
Peter Bohlen - Cortland Manor NY

Assignee:

American Cyanamid Company - Madison NJ

International Classification:

A61K 3165

US Classification:

514152

Abstract:

The invention relates to a method for inhibiting angiogenesis and proliferation of endothelial cells by administering an inhibitory amount of a 9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracycline of Formula I: ##STR1## wherein W, R. sub. 2 and R. sub. 3 are as defined in the specification. The invention also relates to a method for inhibiting proliferation of tumor cells and tumor growth by administering an inhibitory amount of a compound of Formula I in combination with a chemotherapeutic agent or radiation therapy. The invention also relates to compositions containing an effective inhibitory amount of a compound of Formula I in a pharmaceutically acceptable carrier.

US Patent:

58439250, Dec 1, 1998

Filed:

Dec 13, 1994

Appl. No.:

8/354694

Inventors:

Joseph M. Backer - Tenafly NJ
Peter Bohlen - Cortland Manor NY

Assignee:

American Cyanamid Company - Madison NJ

International Classification:

A61K 3165
A61K 926

US Classification:

514152

Abstract:

The invention relates to a method for inhibiting angiogenesis and proliferation of endothelial cells by administering an inhibitory amount of a 7-�substituted amino!-9-�(substituted glycyl)amido!-6-demethyl-6-deoxytetracycline of Formula I: ##STR1## wherein R, R. sub. 2, R. sub. 3, and W are as defined in the specification. The invention also relates to a method for inhibiting proliferation of tumor cells and tumor growth by administering an inhibitory amount of a compound of Formula I in combination with a chemotherapeutic agent or radiation therapy. The invention also relates to compositions containing an effective inhibitory amount of a compound of Formula I in a pharmaceutically acceptable carrier.

US Patent:

55676936, Oct 22, 1996

Filed:

Dec 13, 1994

Appl. No.:

8/354688

Inventors:

Joseph M. Backer - Tenafly NJ
Peter Bohlen - Cortland Manor NY

Assignee:

American Cyanamid Company - Madison NJ

International Classification:

A61K 3165
A61K 4700
A61K 926

US Classification:

514154

Abstract:

The invention relates to a method for inhibiting angiogenesis and proliferation of endothelial cells by administering an inhibitory amount of a 7-(hydrogen or di (C. sub. 1 -C. sub. 4)alkylamino)-8-halogen-9-(substituted)-6-demethyl-6-deoxytetracycl ine of Formula I: ##STR1## wherein R, X and W are as defined in the specification. The invention also relates to a method for inhibiting proliferation of tumor cells and tumor growth by administering an inhibitory amount of a compound of Formula I in combination with a chemotherapeutic agent or radiation therapy. The invention also relates to compositions containing an effective inhibitory amount of a compound of Formula I in a pharmaceutically acceptable carrier.

US Patent:

58563156, Jan 5, 1999

Filed:

May 26, 1998

Appl. No.:

/084484

Inventors:

Joseph M. Backer - Tenafly NJ
Peter Bohlen - Cortland Manor NY

Assignee:

American Cyanamid Company - Madison NJ

International Classification:

A61K 3165
A61K 31025

US Classification:

514152

Abstract:

The invention relates to a method for inhibiting angiogenesis and proliferation of endothelial cells by administering an inhibitory amount of 7-�substituted amino!-9-�(substituted glycyl)amido!-6-demethyl-6-deoxytetracycline of Formula I: ##STR1## wherein R, R. sub. 2, R. sub. 3, and W are as defined in the specification. The invention also relates to a method for inhibiting proliferation of tumor cells and tumor growth by administering an inhibitory amount of a compound of Formula I in combination with a chemotherapeutic agent or radiation therapy. The invention also relates to compositions containing an effective inhibitory amount of a compound of Formula I in a pharmaceutically acceptable carrier.

US Patent:

54610290, Oct 24, 1995

Filed:

Apr 24, 1992

Appl. No.:

7/874848

Inventors:

Joseph M. Backer - Tenafly NJ
Michael R. Ostrander - Glen Ridge NJ

Assignee:

American Cyanamid Company - Wayne NJ

International Classification:

A61K 3816
A61K 3818

US Classification:

514 2

Abstract:

The disclosure relates to a method of inhibiting the infectivity of a virus, the virus being characterized by the presence of a heparin-binding protein, which comprises contacting the cellular receptor for the virus or the receptor-binding protein of the virus with an effective amount of a pharmaceutical composition containing the HBNF protein, the MK protein or a combination thereof in a sufficient amount to inhibit the infectivity of the virus. Also, this disclosure concerns a method of preventing or treating a viral infection in a subject, the virus being characterized by the presence of a heparin-binding protein, which comprises administering to the subject an effective amount of a pharmaceutical composition containing HBNF, MK or a combination thereof in a sufficient amount to prevent or treat the viral infection in the subject. Further, the disclosure describes a new composition comprising a combination of the HBNF and MK proteins. Both HBNF and MK possess heparin-binding activity, displace bFGF from high affinity receptors and inhibit growth of endothelial cells.

US Patent:

55740260, Nov 12, 1996

Filed:

Dec 13, 1994

Appl. No.:

8/355392

Inventors:

Joseph M. Backer - Tenafly NJ
Peter Bohlen - Cortland Manor NY

Assignee:

American Cyanamid Company - Madison NJ

International Classification:

A61K 3165
A61K 31025

US Classification:

514152

Abstract:

The invention relates to a method for inhibiting angiogenesis and proliferation of endothelial cells by administering an inhibitory amount of a 7-halogen-9-[hydrogen or [(substituted glycyl)amido]]-6-demethyl-6-deoxytetracycline of Formula I: ##STR1## wherein X and W are as defined in the specification. The invention also relates to a method for inhibiting proliferation of tumor cells and tumor growth by administering an inhibitory amount of a compound of Formula I in combination with a chemotherapeutic agent or radiation therapy. The invention also relates to compositions containing an effective inhibitory amount of a compound of Formula I in a pharmaceutically acceptable carrier.